Intellia Therapeutics Stock Price on December 1, 2024
| NTLA Stock | USD 15.62 0.41 2.70% |
Below is the normalized historical share price chart for Intellia Therapeutics extending back to May 06, 2016. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Intellia Therapeutics stands at 15.62, as last reported on the 1st of December, with the highest price reaching 15.69 and the lowest price hitting 15.12 during the day.
If you're considering investing in Intellia Stock, it is important to understand the factors that can impact its price. Intellia Therapeutics holds Efficiency (Sharpe) Ratio of -0.0925, which attests that the entity had a -0.0925% return per unit of risk over the last 3 months. Intellia Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Intellia Therapeutics' Standard Deviation of 4.37, risk adjusted performance of (0.07), and Market Risk Adjusted Performance of (0.15) to validate the risk estimate we provide.
At present, Intellia Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 140.8 M, whereas Total Stockholder Equity is forecasted to decline to about 548.5 M. . At present, Intellia Therapeutics' Price Book Value Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.51, whereas Price To Sales Ratio is forecasted to decline to 51.24. Intellia Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of May 2016 | 200 Day MA 22.8452 | 50 Day MA 17.5301 | Beta 1.806 |
Intellia |
Sharpe Ratio = -0.0925
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NTLA |
Estimated Market Risk
| 4.39 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Intellia Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intellia Therapeutics by adding Intellia Therapeutics to a well-diversified portfolio.
Price Book 1.6527 | Enterprise Value Ebitda (5.51) | Price Sales 36.9234 | Shares Float 100.6 M | Wall Street Target Price 59.7793 |
Related Headline
Verve Therapeutics Headline on 1st of December 2024
Acquisition by Fiedorek Fred T. of 90000 shares of Verve The... by Fiedorek Fred T.
Filed transaction by Verve Therapeutics Officer Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Intellia Therapeutics Valuation on December 1, 2024
It is possible to determine the worth of Intellia Therapeutics on a given historical date. On December 1, 2024 Intellia was worth 15.41 at the beginning of the trading date compared to the closed value of 15.62. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Intellia Therapeutics stock. Still, in general, we apply an absolute valuation method to find Intellia Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Intellia Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Intellia Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 15.41 | 15.69 | 15.12 | 15.62 | 1,399,168 | |
12/01/2024 | 15.41 | 15.69 | 15.12 | 15.62 | 0.00 |
| Backtest Intellia Therapeutics | | | Intellia Therapeutics History | | | Intellia Therapeutics Valuation | Previous |
Intellia Therapeutics Trading Date Momentum on December 1, 2024
| On December 01 2024 Intellia Therapeutics was traded for 15.62 at the closing time. The top price for the day was 15.69 and the lowest listed price was 15.12 . There was no trading activity during the period 0.0. Lack of trading volume on December 1, 2024 did not cause price change. The trading delta at closing time against the current closing price is 1.34% . |
Intellia Therapeutics Fundamentals Correlations and Trends
By evaluating Intellia Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Intellia financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Intellia Therapeutics Stock history
Intellia Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Intellia is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Intellia Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Intellia Therapeutics stock prices may prove useful in developing a viable investing in Intellia Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 88.8 M | 50.5 M | |
| Net Loss | -426.8 M | -405.4 M |
Intellia Therapeutics Quarterly Net Working Capital |
|
Intellia Therapeutics Stock Technical Analysis
Intellia Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Intellia Therapeutics Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Intellia Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Intellia Therapeutics December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Intellia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Intellia Therapeutics shares will generate the highest return on investment. By undertsting and applying Intellia Therapeutics stock market strength indicators, traders can identify Intellia Therapeutics entry and exit signals to maximize returns
Intellia Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Intellia Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Intellia Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Intellia to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.16) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world |